Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRIHEXYPHENIDYL HYDROCHLORIDE vs AMRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Adjunctive therapy for all forms of Parkinson's disease,Treatment of drug-induced extrapyramidal symptoms (e.g., neuroleptic-induced parkinsonism, acute dystonia, akathisia)
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
10-17 hours; clinical context: steady-state concentrations achieved in 2-3 days.
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Primarily metabolized by hepatic microsomal enzymes, with CYP2D6 possibly involved. Elimination half-life is approximately 3–4 hours.
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Renal (primarily as unchanged drug and metabolites; <15% unchanged) and biliary/fecal (minor).
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Minimal; approximately 10-20% bound to plasma proteins (albumin).
40–45% bound to serum proteins, primarily albumin
Approximately 0.5-1.5 L/kg; indicates extensive tissue distribution.
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
Oral: approximately 80-95% (first-pass metabolism minimal).
Oral: 85–95% (extended-release formulation)
Cr Cl 10-50 m L/min: administer every 8-12 hours; Cr Cl <10 m L/min: consider alternative or reduce dose by 50%.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or use with extreme caution, reduce dose by 75%.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Children 2-12 years: initial 1 mg/day, increase by 1 mg every 3-5 days; maximum 6 mg/day in divided doses.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
Start at 1 mg once or twice daily; increase slowly by 1 mg increments every 5-7 days; monitor for anticholinergic side effects.
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
Not applicable.
None
May cause drowsiness, dizziness, or blurred vision; caution with driving or hazardous activities,Anticholinergic effects may be exacerbated in elderly patients, including confusion, constipation, urinary retention, and hyperthermia,Use cautiously in patients with glaucoma, prostatic hypertrophy, cardiac arrhythmias, or myasthenia gravis,Potential for abuse or dependence at high doses,May exacerbate tardive dyskinesia in patients on neuroleptics
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
Hypersensitivity to trihexyphenidyl,Narrow-angle glaucoma,Obstructive gastrointestinal disorders (e.g., pyloric stenosis, paralytic ileus),Severe ulcerative colitis or toxic megacolon,Myasthenia gravis
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
No significant food interactions. However, avoid excessive alcohol consumption as it may exacerbate CNS depression and anticholinergic effects. Maintain adequate hydration to prevent constipation and dry mouth.
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: No known specific risks; use only if clearly needed.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
No data on M/P ratio; excreted in breast milk in unknown amounts. Caution recommended; avoid if possible.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
No established pharmacokinetic changes requiring dose adjustment; usual therapeutic dose maintained; monitor clinical response.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
Trihexyphenidyl is an anticholinergic agent used primarily for drug-induced parkinsonism and idiopathic Parkinson disease. It is less effective than levodopa but useful as adjunctive therapy. Onset of action is within 1 hour after oral administration; peak effect at 2-3 hours. Monitor for anticholinergic side effects: dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment. Use with caution in elderly patients due to increased risk of confusion and falls. Abrupt withdrawal may precipitate parkinsonian crisis; taper gradually. Avoid in patients with narrow-angle glaucoma, myasthenia gravis, or gastrointestinal obstruction.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,This medication may cause dry mouth, blurred vision, constipation, or difficulty urinating.,Avoid alcohol and other CNS depressants as they may increase drowsiness and dizziness.,Use caution when driving or operating machinery until you know how this drug affects you.,Report any eye pain, vision changes, or difficulty passing urine to your healthcare provider.,Do not chew sustained-release capsules; swallow whole.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double doses.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
"Trihexyphenidyl, an anticholinergic agent, may potentiate the tachycardic effects of nabilone, a synthetic cannabinoid, due to additive inhibition of parasympathetic tone. This interaction can lead to clinically significant sinus tachycardia, palpitations, and potentially exacerbate underlying cardiovascular conditions such as coronary artery disease or arrhythmias."
"The concurrent use of trihexyphenidyl, an anticholinergic agent, with meperidine, an opioid analgesic, increases the risk of severe adverse effects such as central nervous system depression, respiratory depression, and anticholinergic toxicity (e.g., delirium, hyperthermia, and urinary retention). This additive pharmacodynamic interaction occurs due to combined anticholinergic and opioid properties, potentially leading to life-threatening outcomes, especially in elderly or debilitated patients. Clinicians should consider alternative therapies or closely monitor for signs of excessive sedation, respiratory compromise, and anticholinergic crisis."
"Donepezil, a cholinesterase inhibitor used in Alzheimer's disease, increases acetylcholine levels in the central nervous system. Trihexyphenidyl, an anticholinergic agent for Parkinson's disease, blocks muscarinic acetylcholine receptors. Concurrent use results in functional antagonism, where trihexyphenidyl's anticholinergic effects diminish the efficacy of donepezil, potentially worsening cognitive function in Alzheimer's patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRIHEXYPHENIDYL HYDROCHLORIDE vs AMRIX, answered by our medical review team.
TRIHEXYPHENIDYL HYDROCHLORIDE is a Anticholinergic Antiparkinsonian that works by Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.. AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRIHEXYPHENIDYL HYDROCHLORIDE and AMRIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRIHEXYPHENIDYL HYDROCHLORIDE is: 1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.. The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRIHEXYPHENIDYL HYDROCHLORIDE and AMRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRIHEXYPHENIDYL HYDROCHLORIDE is classified as Category C. First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: No known specific risks; use only if clearly needed.. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.